A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
NCT ID: NCT00035035
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GEMZAR
ALIMTA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* You must have one tumor that can be physically measured or scanned by the doctor.
* You have not had any chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for pancreas cancer, including 5-FU.
* You cannot have any radiation for 4 weeks before starting this study, and you cannot have radiation to the whole pelvis.
Exclusion Criteria
* Documentation that the cancer has spread to your brain.
* Pregnant or breastfeeding.
* A second primary cancer.
* Unable to stop aspirin or non-steroidal anti-inflammatory agents (like ibuprofen) for 5-8 days.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Fountain Valley, California, United States
Fullerton, California, United States
Lancaster, California, United States
Los Angeles, California, United States
Pomona, California, United States
Santa Rosa, California, United States
Torrance, California, United States
Fort Collins, Colorado, United States
Hartford, Connecticut, United States
Lake Worth, Florida, United States
Miami, Florida, United States
Chicago, Illinois, United States
Decatur, Illinois, United States
Harvey, Illinois, United States
Indianapolis, Indiana, United States
Wichita, Kansas, United States
Crestview Hills, Kentucky, United States
Louisville, Kentucky, United States
Lafayette, Louisiana, United States
Shreveport, Louisiana, United States
Scarborough, Maine, United States
Burlington, Massachusetts, United States
Omaha, Nebraska, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Canton, Ohio, United States
Cleveland, Ohio, United States
Drexel Hill, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Columbia, South Carolina, United States
Johnson City, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Tyler, Texas, United States
Tacoma, Washington, United States
Marshfield, Wisconsin, United States
Milwaukee, Wisconsin, United States
Capitol Federal, Buenos Aires, Argentina
Mendoza, Mendoza Province, Argentina
Santa Fe, Rosario, Argentina
Ciudad de Buenos Aires, , Argentina
Bankstown, New South Wales, Australia
Kingswood Penrith, New South Wales, Australia
Wollongong, New South Wales, Australia
Southport, Queensland, Australia
Fitzroy, Victoria, Australia
Frankston, Victoria, Australia
Innsbruck, , Austria
Saint Veit Glan, , Austria
Vienna, , Austria
Brussels, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Cali, , Colombia
Strasbourg, Cedex, France
Lille, , France
Marseille, , France
Paris, , France
Rennes, , France
Rouen, , France
Toulouse, , France
Bielefeld, Nordhein-Westfalen, Germany
Berlin, , Germany
Bremerhaven, , Germany
Frankfurt, , Germany
Kaiserslautern, , Germany
Karlsruhe, , Germany
Magdeburg, , Germany
Mannheim, , Germany
München, , Germany
Neustadt/Suedharz, , Germany
Stuttgart, , Germany
Marousi, Athens, Greece
Ioannina, , Greece
Genova, , Italy
Ravenna, , Italy
Roma, , Italy
Breda, , Netherlands
Enschede, , Netherlands
Roermond, , Netherlands
Sittard, , Netherlands
The Hague, , Netherlands
Chiclayo, , Peru
Lima, , Peru
Lisbon, , Portugal
Porto, , Portugal
Santa Maria da Feira, , Portugal
Santarém, , Portugal
Elche, Alicante, Spain
Barcelona, Barcelona, Spain
Madrid, Madrid, Spain
Santa Cruz de Tenerife, Santa Cruz De Tenerife, Spain
Zaragoza, Zaragoza, Spain
Linköping, , Sweden
Lund, , Sweden
Malmo, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Taoyuan District, Kuei-Shan, Taiwan
Yungkang City, Tainan, Taiwan
Tainan City, , Taiwan
Taipei, , Taiwan
Bristol, Avon, United Kingdom
Hull, East Yorkshire, United Kingdom
Acton, London, United Kingdom
Northwood, Middlesex, United Kingdom
Belfast, Northern Ireland, United Kingdom
Manchester, , United Kingdom
Valencia, Edo. Aragua, Venezuela
Estado Aragua, Maracay, Venezuela
Caracas, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H3E-MC-JMES
Identifier Type: -
Identifier Source: secondary_id
5148
Identifier Type: -
Identifier Source: org_study_id
NCT00049426
Identifier Type: -
Identifier Source: nct_alias